CA2827082A1 - Methods of treating macular edema using antiedema therapeutics - Google Patents

Methods of treating macular edema using antiedema therapeutics Download PDF

Info

Publication number
CA2827082A1
CA2827082A1 CA2827082A CA2827082A CA2827082A1 CA 2827082 A1 CA2827082 A1 CA 2827082A1 CA 2827082 A CA2827082 A CA 2827082A CA 2827082 A CA2827082 A CA 2827082A CA 2827082 A1 CA2827082 A1 CA 2827082A1
Authority
CA
Canada
Prior art keywords
letters
months
patients
normal
visual acuity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2827082A
Other languages
English (en)
French (fr)
Inventor
Paul Ashton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of CA2827082A1 publication Critical patent/CA2827082A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2827082A 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics Abandoned CA2827082A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442151P 2011-02-11 2011-02-11
US61/442,151 2011-02-11
PCT/US2012/024910 WO2012109673A1 (en) 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics

Publications (1)

Publication Number Publication Date
CA2827082A1 true CA2827082A1 (en) 2012-08-16

Family

ID=46637026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827082A Abandoned CA2827082A1 (en) 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics

Country Status (8)

Country Link
US (1) US20120207682A1 (https=)
EP (1) EP2673049A4 (https=)
JP (1) JP2014508749A (https=)
CN (1) CN103402582A (https=)
AU (1) AU2012214146A1 (https=)
CA (1) CA2827082A1 (https=)
RU (1) RU2013138180A (https=)
WO (1) WO2012109673A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2968882B1 (en) * 2013-03-12 2021-05-19 EyePoint Pharmaceuticals US, Inc. Drug delivery device comprising silicon-based carrier particles
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
SG10201809363SA (en) * 2013-11-15 2018-11-29 Allergan Inc Methods of treatment of ocular conditions with a sustained drug delivery implant
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EP4537830A3 (en) 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ575950A (en) * 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles

Also Published As

Publication number Publication date
AU2012214146A1 (en) 2013-08-29
RU2013138180A (ru) 2015-03-20
CN103402582A (zh) 2013-11-20
EP2673049A4 (en) 2015-04-08
US20120207682A1 (en) 2012-08-16
EP2673049A1 (en) 2013-12-18
JP2014508749A (ja) 2014-04-10
WO2012109673A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
US20120207682A1 (en) Methods of treating macular edema using antiedema therapeutics
Campochiaro et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert
TWI332846B (en) Ocular implant made by a double extrusion process
CN115531352B (zh) 可生物蚀解的眼部药物递送插入剂及治疗方法
KR20060085246A (ko) 경공막 전달
JP2014508749A5 (https=)
BRPI0613401A2 (pt) terapia ocular usando derivados de glicocorticóides que penetram seletivamente nos tecidos do segmento posterior
Eperon et al. A biodegradable drug delivery system for the treatment of postoperative inflammation
de Smet Corticosteroid intravitreal implants
CA2830555A1 (en) Intraocular drug delivery device and associated methods
TW202400143A (zh) 用於治療眼睛病況之持續給藥方案
US20160317438A1 (en) Injectable sustained release intraocular device
Eperon et al. A new drug delivery system inhibits uveitis in an animal model after cataract surgery
US10588855B2 (en) Intraocular drug delivery device and associated methods
JP2010522774A (ja) 血管新生眼疾患を治療するための方法
AU2017388230A1 (en) Intraocular drug delivery device and associated methods
JP2011513337A (ja) 椎間板ヘルニアを治療するための方法および組成物
US20240058264A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
US20240108500A1 (en) Implant
Kiss Sustained-release corticosteroid delivery systems
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
Jaffe Fluocinolone acetonide sustained drug-delivery implant for posterior segment eye diseases
HK40118701A (zh) 用於治疗眼睛病症的持续给药方案
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180213